Mythily Srinivasan
Permanent URI for this collection
Unresolved inflammation and altered immune signals contribute to the pathology of many chronic diseases. Dr. Srinivasan's research includes the design and development of immunotherapeutic peptides using motif-mediated protein-protein interactions as drug targets.
Recently, she investigated approaches to suppress neuroinflammation in Alzheimer's disease, the most common cause of dementia that is projected to affect over seven million individuals in the United States by 2025. These studies resulted from earlier observations that the blockade of T cell co-receptor CD28 by CD80 competitive antagonist peptides unregulated glucocorticoid-induced leucine zipper (GILZ)-an anti-inflammatory molecule that directly inhibits the pro-inflammatory transcription factor, nuclear factor-kappa B (NF-kB).
Adopting data from the GILZ and NF-kB interaction complex, Dr. Srinivasan developed modified analogs of the p65 binding motif of GIlZ. Efficacy studies, in collaboration with Dr. Debomoy Lahiri, Professor of Neuroscience, and Dr. Deborah Hickman of the IU School of Medicine, suggested that the novel therapeutics exhibited suppressive potential in cellular and animal models of Alzheimer's disease.
Together with the Indiana University Research and Technology Corporation, Dr. Srinivasan initiated a startup venture, Provaidya LLC, to develop the patented GILZ analogs as investigational new drugs and received phase I funding from the National Institutes of Aging.
Dr. Srinivasan's work to develop peptide therapeutics to suppress neuroinflammation is another example of how IUPUI faculty are TRANSLATING RESEARCH INTO PRACTICE.